JP2013527168A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527168A5
JP2013527168A5 JP2013508244A JP2013508244A JP2013527168A5 JP 2013527168 A5 JP2013527168 A5 JP 2013527168A5 JP 2013508244 A JP2013508244 A JP 2013508244A JP 2013508244 A JP2013508244 A JP 2013508244A JP 2013527168 A5 JP2013527168 A5 JP 2013527168A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
protein
composition according
item
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013508244A
Other languages
English (en)
Japanese (ja)
Other versions
JP5899206B2 (ja
JP2013527168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/034282 external-priority patent/WO2011139820A1/en
Publication of JP2013527168A publication Critical patent/JP2013527168A/ja
Publication of JP2013527168A5 publication Critical patent/JP2013527168A5/ja
Application granted granted Critical
Publication of JP5899206B2 publication Critical patent/JP5899206B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013508244A 2010-04-28 2011-04-28 関節リウマチの治療のための可溶性ｃｄ２４の使用方法 Expired - Fee Related JP5899206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
US61/329,078 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015137457A Division JP6062502B2 (ja) 2010-04-28 2015-07-09 関節リウマチの治療のための可溶性ｃｄ２４の使用方法

Publications (3)

Publication Number Publication Date
JP2013527168A JP2013527168A (ja) 2013-06-27
JP2013527168A5 true JP2013527168A5 (enExample) 2014-06-19
JP5899206B2 JP5899206B2 (ja) 2016-04-06

Family

ID=44903987

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013508244A Expired - Fee Related JP5899206B2 (ja) 2010-04-28 2011-04-28 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2015137457A Expired - Fee Related JP6062502B2 (ja) 2010-04-28 2015-07-09 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2016242313A Withdrawn JP2017057216A (ja) 2010-04-28 2016-12-14 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2018094404A Expired - Fee Related JP6526872B2 (ja) 2010-04-28 2018-05-16 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2019088170A Expired - Fee Related JP6888221B2 (ja) 2010-04-28 2019-05-08 関節リウマチの治療のための可溶性ｃｄ２４の使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015137457A Expired - Fee Related JP6062502B2 (ja) 2010-04-28 2015-07-09 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2016242313A Withdrawn JP2017057216A (ja) 2010-04-28 2016-12-14 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2018094404A Expired - Fee Related JP6526872B2 (ja) 2010-04-28 2018-05-16 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP2019088170A Expired - Fee Related JP6888221B2 (ja) 2010-04-28 2019-05-08 関節リウマチの治療のための可溶性ｃｄ２４の使用方法

Country Status (17)

Country Link
US (1) US8808697B2 (enExample)
EP (3) EP2563385B1 (enExample)
JP (5) JP5899206B2 (enExample)
KR (1) KR20130086126A (enExample)
CN (2) CN105381451B (enExample)
AU (1) AU2011248540B2 (enExample)
CA (1) CA2795823C (enExample)
DK (1) DK2563385T3 (enExample)
EA (2) EA036805B8 (enExample)
ES (2) ES2826445T3 (enExample)
IL (1) IL222739A0 (enExample)
NO (1) NO2563385T3 (enExample)
NZ (1) NZ603196A (enExample)
PL (2) PL2563385T3 (enExample)
PT (2) PT3260128T (enExample)
SG (1) SG184907A1 (enExample)
WO (1) WO2011139820A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
US10799558B2 (en) 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
CN110650749A (zh) * 2017-05-15 2020-01-03 肿瘤免疫股份有限公司 使用可溶性cd24进行神经保护和髓鞘再生的方法
EP3630158B1 (en) * 2017-05-22 2022-07-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
SG11202010589YA (en) * 2018-05-14 2020-11-27 Oncoimmune Inc Anti-cd24 compositions and uses thereof
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
CN118076625A (zh) * 2021-09-28 2024-05-24 广州昂科免疫生物技术有限公司 包含071核心肽的融合蛋白及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
CN100594037C (zh) * 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
ME00426B (me) * 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
AU2004294547A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
WO2006053245A2 (en) * 2004-11-12 2006-05-18 Iogenetics, Llc Retroviral vectors with introns

Similar Documents

Publication Publication Date Title
RU2437893C2 (ru) Варианты il-7 со сниженной иммуногенностью
Yuan et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
Ko et al. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
US20240254185A1 (en) Interleukin-2 variants and methods of uses thereof
US6458360B1 (en) Soluble complement regulatory molecules
ES3037854T3 (en) D-domain containing polypeptides and uses thereof
ES2552954T3 (es) Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
ES2968439T3 (es) Anticuerpos FcRn y procedimientos de uso de los mismos
RU2015142999A (ru) Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения
NO324047B1 (no) Hoyaffinitetshumane monoklonale antistoff spesifikke for RSV F-protein samt anvendelse derav
ES2655941T3 (es) Proteína de fusión
JP2017527272A5 (enExample)
JP2015500811A5 (enExample)
JP2018515605A5 (enExample)
CA2398521A1 (en) Compositions and methods for inhibition of hiv-1 infection
Geng et al. Cartilage oligomeric matrix protein specific antibodies are pathogenic
JPH0372430A (ja) 細胞間粘着分子の官能性誘導体を用いた抗ウィルス剤
EA036805B1 (ru) Белок cd24 для подавления повреждения ткани, опосредованного damp
RS20080471A (sr) Upotreba antagonista subjedinice alfa-4 integrina za pripremanje farmaceutskog preparata za tretiranje fibroze
Groß et al. Mimicking protein–protein interactions through peptide–peptide interactions: HIV-1 gp120 and CXCR4
US20150037333A1 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
JP2019506408A5 (enExample)
Kowalczyk et al. Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies
JP2020519627A5 (enExample)
CN113271968B (zh) 经修饰的巨细胞病毒蛋白和稳定化的复合物